Clinical Trial Search

Primary: Change in Fasting Plasma Glucose Concentration — 4.7; 0.0 mmol/l

Primary: Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy — -39.9; 5.4 Percent change in LDL-c — p=<0.0001

Primary: Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM) — -4.94; -10.00; -1.21; -11.42 mg/dL…

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — 0.46; 0.18; -0.07; 0.01 Percentage of HbA1c — p=0.061

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 1; 1 participants

Primary: Number of Participants With Abnormal Physical Examination Findings

Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), or Serious Adverse Events (SAEs), or Hypoglycemic Adverse Events (HAE) or Withdrawals Due to…

Primary: Change in Muscle Oxygen Saturation — -10.7127; -8.9149; -12.471; -8.7883 percentage

Primary: Disposition Index — 0.023; 0.149 index

Primary: Number of Participants With All-Causality and Treatment Related Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events — 5; 3; 3; 5 participants

Primary: Number of Participants With Adverse Events [Safety and Tolerability of GLY-200] — 9; 8; 12; 7 Participants

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 — -0.46; -0.25; -0.71; -1.08 Percentage of HbA1c in the blood — p=0.2968

Primary: Number of Participants With Treatment-emergent Adverse Events (All Causalities) — 5; 7; 6; 0 Participants

Primary: Number of Participants With Clinically Significant Adverse Effects — 0; 0; 1; 0 participants

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 1; 1; 4; 3 Participants

Primary: Change in Absolute Gluconeogenesis From Baseline to 12 Weeks — 0.018; -0.050 mg/kg LBM/min

Primary: Number of Participants Had Protocol-Defined Total Hypoglycemic Adverse Event (HAE) - Part A — 2; 2; 1; 1 participants

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) Through the End of the Up-titration Period…

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 1; 4; 1; 3 participants

Primary: Change From Baseline for Mean Hemoglobin A1c (HbA1C) — 6.9; -0.5 Percent of glycosylated hemoglobin

Primary: Change From Baseline in Homeostatic Model Assessment Fasting Beta Cell Function (HOMA % B) at 4 Years — 50.2; 48.3 Percentage of Beta Cell Function — p=0.24

Primary: Number of Participants With Abnormal Physical Examination Findings

Primary: Number of Participants With Any Adverse Event (AE), Serious Adverse Event (SAE), AE Related to Study Medication, AE Leading to Discontinuation and Fatal AE of Death…

Primary: Continuous Glucose Monitoring (CGM) — -6.23; -0.72 Percentage of day (24h) in euglycemia

Primary: Percent of All Glucose Values Within Glucose Range < 70 mg/dL — 0 Percentage of all glucose values

Primary: For Transition From Inpatient to Outpatient Care, Evaluate Glycemic Control in Subjects Randomized to Receive 70/30 NPH/Regular Insulin or Aspart Analog 70/30 Mix Bid…

Primary: Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo — -5.2; -9.4; -8.8 umol/L — p=0.57

Primary: Change From Baseline in A1C at Week 24 — -0.61; -0.76; 0.18 Percent — p=<0.001

Primary: Number of Participants Who Experienced at Least One Adverse Event — 1; 1; 0; 1 participants